Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 96, Issue -, Pages 360-368Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2015.04.031
Keywords
Copper(II) complex; Anticancer activity; Cell apoptosis; Anticancer mechanism; Bcl-2 family proteins
Categories
Funding
- Natural Science Foundation of China [31460232, 21431001, 21171043]
- Natural Science Foundation of Guangxi [2012GXNSFCB053001, 2013GXNSFGA019010, 2014GXNSFDA118016]
- Technology division of Guilin [20130403-1]
- Guangxi 'Bagui' scholar program
Ask authors/readers for more resources
Copper (Cu) compounds are a promising candidate for next generation metal anticancer drugs and have been extensively studied. Therefore, four binuclear copper(II) compounds derived from Schiff base thiosemicarbazones (L1-L4), namely [CuCI(L1)](2) (C1), [CuNO3(L2)](2) (C2), [Cu(NCS) (L3)](2) (C3) and [Cu(CH3COO) (L4)](2) (C4) were synthesized and characterized. Four of these compounds showed very high cytotoxicity to cancer cell lines in vitro. These Cu(II) compounds strongly promoted the apoptosis of BEL-7404 cells. The formation of reactive oxygen species (ROS), change in mitochondrial membrane potential and western blot analysis revealed that Cu compounds could induce cancer cell apoptosis through the intrinsic ROS-mediated mitochondrial pathway accompanied by the regulation of Bcl-2 family proteins. (C) 2015 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available